AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
Filed with ASX · · 2 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- DEP docetaxel positive phase 1 results, phase 2 commences
- Starpharma and Monash awarded STEM Business Fellowships
- Successful VivaGel Phase 3 results and NDA planned for rBV
- VivaGel BV phase 3 results timing and commercialisation
- Starpharma sells Agrochemicals business to Agrium for $35M
Later from Starpharma
- Starpharma and Peter Mac Cancer Centre awarded DEP Grant
- VivaGel BV granted marketing approval in Australia
- NDA submission for VivaGel BV in the US
- VivaGel BV treatment clinical submission under rolling NDA
- Starpharma to commence DEP cabazitaxel phase 1/2 trial
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma